Myriad Genetics (MYGN) Current Assets (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Current Assets data on file, last reported at $312.8 million in Q1 2026.

• Current Assets for Q1 2026 came in at $312.8 million, up 8.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $312.8 million (up 8.91% YoY), and the FY2025 annual result was $332.6 million, up 11.61% from the prior year.
• Current Assets eased to $312.8 million in Q1 2026 per MYGN's latest filing, from $332.6 million in the prior quarter.
• Over five years, Current Assets peaked at $427.4 million in Q1 2022 and troughed at $261.6 million in Q1 2023.
• A 5-year average of $311.2 million and a median of $294.3 million in 2023 frame the typical range for Current Assets.
• On a YoY basis, Current Assets climbed as much as 29.83% in 2022 and fell as far as 43.36% in 2022.
• A 5-year view of Current Assets shows it stood at $274.6 million in 2022, then grew by 14.2% to $313.6 million in 2023, then decreased by 4.97% to $298.0 million in 2024, then rose by 11.61% to $332.6 million in 2025, then dropped by 5.95% to $312.8 million in 2026.
• Business Quant data shows MYGN's Current Assets at $312.8 million in Q1 2026, $332.6 million in Q4 2025, and $344.8 million in Q3 2025.